{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-018424","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2023-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.091265+00:00","generated_at":"2026-06-14T23:33:21.170998+00:00","sec_items":["1.01","3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"X4 Pharma announces $65M PIPE and positive Phase 3 mavorixafor data in WHIM syndrome","bullets":["42.8M shares/pre-funded warrants priced at $1.52, raising $65M gross; expected close May 18, 2023.","Phase 3 4WHIM trial: mavorixafor reduced annualized infection rate by ~60% vs placebo (p<0.01).","Severe (Grade≥3) infections cut by 75%; mean infection duration reduced >70% (2 weeks vs 7 weeks on placebo).","NDA submission for mavorixafor in WHIM syndrome on track for early 2H 2023 after pre-NDA meeting with FDA.","Cash runway extended into Q4 2024, excluding potential priority review voucher proceeds."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-018424","json":"https://secwatch.observer/filing/0001628280-23-018424.json","markdown":"https://secwatch.observer/filing/0001628280-23-018424.md","text":"https://secwatch.observer/filing/0001628280-23-018424.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023018424/0001628280-23-018424-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023018424/xfor-20230515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T23:33:21.170998+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}